文献速递临床试验与 GCP

急性冠脉综合征患者冠状动脉手术后替格瑞洛加阿司匹林与单用阿司匹林的比较

Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.
PubMed 文献 · N Engl J Med · 2025-09-01

在这项开放标签、基于注册的临床试验中,2201例因急性冠脉综合征接受冠状动脉旁路移植术的患者随机接受替格瑞洛加阿司匹林或单用阿司匹林治疗1年。主要复合终点(死亡、心肌梗死、卒中或再次血运重建)发生率两组无显著差异(4.8% vs 4.6%;HR 1.06;95%CI 0.72-1.56;P=0.77)。替格瑞洛加阿司匹林组净不良临床事件和大出血发生率更高。

要点

  • 替格瑞洛加阿司匹林与单用阿司匹林相比,1年主要复合终点发生率无显著差异(4.8% vs 4.6%;HR 1.06;95%CI 0.72-1.56;P=0.77)。
  • 替格瑞洛加阿司匹林组净不良临床事件发生率为9.1%,单用阿司匹林组为6.4%(HR 1.45;95%CI 1.07-1.97)。
  • 替格瑞洛加阿司匹林组大出血发生率为4.9%,单用阿司匹林组为2.0%(HR 2.50;95%CI 1.52-4.11)。

核心结论

  • 因急性冠脉综合征接受冠状动脉旁路移植术的患者中,替格瑞洛加阿司匹林在1年时并未较单用阿司匹林降低死亡、心肌梗死、卒中或再次冠状动脉血运重建的发生率。

研究设计与样本

  • 开放标签、基于注册的临床试验,在22个北欧心胸外科中心进行,患者按1:1随机分配接受替格瑞洛加阿司匹林或单用阿司匹林治疗1年。
  • 共随机分配2201例患者,替格瑞洛加阿司匹林组1104例,单用阿司匹林组1097例;患者平均年龄66岁,女性占14.4%。

主要发现

  • 主要终点事件(死亡、心肌梗死、卒中或再次血运重建)在替格瑞洛加阿司匹林组发生53例(4.8%),单用阿司匹林组发生50例(4.6%)(HR 1.06;95%CI 0.72-1.56;P=0.77)。
  • 净不良临床事件(主要终点事件或大出血)在替格瑞洛加阿司匹林组发生率为9.1%,单用阿司匹林组为6.4%(HR 1.45;95%CI 1.07-1.97)。
  • 大出血在替格瑞洛加阿司匹林组发生率为4.9%,单用阿司匹林组为2.0%(HR 2.50;95%CI 1.52-4.11)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients benefit from antiplatelet therapy after coronary-artery bypass grafting (CABG) for an acute coronary syndrome. Whether the addition of ticagrelor to aspirin, as compared with aspirin alone, further reduces the risk of adverse cardiovascular outcomes is unclear. METHODS: In this open-label, registry-based, clinical trial conducted at 22 Nordic cardiothoracic surgery centers, we randomly assigned patients in a 1:1 ratio to receive either ticagrelor plus aspirin or aspirin alone for 1 year after CABG for an acute coronary syndrome. The primary outcome was a composite of death, myocardial infarction, stroke, or repeat revascularization, evaluated at 1 year. A key secondary outcome was net adverse clinical events, defined as a primary-outcome event or major bleeding. RESULTS: A total of 2201 patients were randomly assigned to receive ticagrelor plus aspirin (1104 patients) or aspirin alone (1097 patients). The mean age of the patients was 66 years, and 14.4% were women. A primary-outcome event occurred in 53 patients (4.8%) in the ticagrelor-plus-aspirin group and 50 (4.6%) in the aspirin-alone group (hazard ratio, 1.06; 95% confidence interval [CI], 0.72 to 1.56; P = 0.77). Net adverse clinical events occurred in 9.1% of patients in the ticagrelor-plus-aspirin group and 6.4% in the aspirin-alone group (hazard ratio, 1.45; 95% CI, 1.07 to 1.97). Major bleeding occurred in 4.9% of patients in the ticagrelor-plus-aspirin group and 2.0% in the aspirin-alone group (hazard ratio, 2.50; 95% CI, 1.52 to 4.11). CONCLUSIONS: Among patients who underwent CABG for an acute coronary syndrome, ticagrelor plus aspirin did not result in a lower incidence of death, myocardial infarction, stroke, or repeat coronary revascularization than aspirin alone at 1 year. (Funded by the Swedish Research Council and others; TACSI ClinicalTrials.gov number, NCT03560310; EudraCT number, 2017-001499-43; EU Clinical Trials number, 2023-508551-40-00.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Jeppsson A, James S, Moller CH, et al. Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome. N Engl J Med. 2025. PMID: 40888737. doi:10.1056/NEJMoa2508026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。